The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
NASHVILLE, Tenn.--(BUSINESS WIRE)--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced the completion of the transfer to Harrow of the New Drug Applications (NDAs) ...
CEO Mark Baum highlighted, “Harrow now owns one of the largest portfolios of prescription ophthalmic products in the United States market, and we have been the most prolific acquirer of ophthalmic ...
"Looking ahead to the second quarter, we expect total revenues to be in the range of $71 million to $81 million." (CFO Boll) "We're fully reaffirming our 2026 revenue guidance of between $350 million ...
NYSE:DY: $25.2 million (1.9% of AUM) NYSE:AMTM: $23.1 million (1.8% of AUM) NASDAQ:ATEC: $22.8 million (1.8% of AUM) NASDAQ:MIRM: $22.6 million (1.7% of AUM) NASDAQ:WFRD: $22.3 million (1.7% of AUM) ...
Graduates from 12 nationalities earn places at top universities across the UK, USA, Japan, Canada, Australia and beyond — ...
NASHVILLE, Tenn.--(BUSINESS WIRE)--Harrow (NASDAQ: HROW), a leading U.S. eyecare pharmaceutical company, today announced results for the fourth quarter and year ended December 31, 2022. The Company ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results